Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
sales@dingminpharma.com
86-311-67591193
Model No.: DM 261953-36-0
Purity: 99%
Appearence: Colorless Liquid
Packaging: Double PE Bag with Foil Bag or As required
Productivity: Stock available
Transportation: Ocean,Air,Courier
Place of Origin: Hebei,China
Supply Ability: As per order
Certificate: ISO9001
Port: Shanghai,Shenzhen,Hangzhou
Payment Type: L/C,T/T,D/P
Incoterm: FOB,CIF,CIP
6-Iodo-1H-Indazole CAS No.261953-36-0 Axitinib Intermediate:
Axitinib is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation are the most common side effects occurring in more than 20% of patients
Product Name: 3-6-Iodo-1H-Indazole; 6-IODOINDAZOLE
Cas No.: 261953-36-0
EINECS No: 607-884-2
Moculer formula: C7H5IN2
Moculer weight: 244.03
Appearance: White to brown powder
Purity(By HPLC): ≥99.0%
Water:≤0.5%
Single Impurity: ≤0.5%
Shelf time: 2 years
Our productions of Axitinib Intermediates:
Product Categories : APIs And Intermediates > Axitinib Intermediates
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.